Key Takeaways
- Can-Fite BioPharma (CANF) shares rocketed up to 65% on Wednesday following the release of Phase 2a clinical data for Namodenoson in patients with advanced pancreatic cancer.
- The trial successfully achieved its primary safety objective among 20 participants who had previously failed standard treatment options.
- Among third-line treatment patients, median overall survival surpassed five months, with more than one-third surviving beyond seven months.
- A patient receiving second-line treatment remained alive beyond 18 months after initiating Namodenoson therapy, representing the trial’s longest-surviving participant.
- The company intends to progress Namodenoson into Phase 2b testing combining the drug with chemotherapy agents.
Can-Fite BioPharma (CANF) shares experienced a dramatic rally of up to 65% during Wednesday’s trading session after the biotech firm unveiled clinical findings from its Phase 2a evaluation of Namodenoson in patients suffering from advanced pancreatic ductal adenocarcinoma (PDAC). Trading activity positioned the stock near $2.97 per share in the wake of the news.
The open-label clinical investigation included 20 participants, each of whom had previously experienced disease progression despite receiving conventional therapeutic interventions. The patient distribution consisted of fourteen individuals receiving Namodenoson as third-line treatment, five receiving it as second-line therapy, and one receiving it as fourth-line treatment.
The clinical trial successfully reached its primary safety objective. Namodenoson demonstrated favorable tolerability, maintaining a safety profile aligned with previous clinical investigations.
An updated survival assessment focused on eight evaluable third-line patients who maintained survival for a minimum of two months following treatment initiation revealed that median overall survival exceeded the five-month threshold. This represents a significant benchmark in a disease context where therapeutic alternatives are severely restricted at advanced stages.
Among this patient cohort, 62.5% maintained survival beyond five months. Additionally, 37.5% achieved survival extending past seven months. Two participants remained alive when data collection concluded.
The second-line treatment cohort yielded a particularly striking observation. One individual continued living more than 18 months after commencing Namodenoson therapy, establishing the longest survival duration documented throughout the entire investigation.
Expert Commentary on Trial Outcomes
Prof. Salomon Stemmer, the principal investigator overseeing the Phase 2a investigation at the Davidoff Institute of Oncology within Israel’s Rabin Medical Center, characterized the Namodenoson monotherapy outcomes as “impressive.”
He highlighted the drug’s encouraging safety characteristics and the extended survival observed among a patient subset as indicators of meaningful biological activity warranting additional exploration. According to Stemmer, the appropriate next phase involves assessing Namodenoson alongside chemotherapy regimens.
Preclinical research has demonstrated the compound’s capacity to amplify the anti-tumor effectiveness of chemotherapeutic drugs in pancreatic cancer experimental models, establishing the scientific foundation for subsequent development.
Future Development Plans
Can-Fite is preparing to advance Namodenoson into a Phase 2b combination trial incorporating chemotherapy, leveraging both the Phase 2a clinical outcomes and supporting preclinical evidence.
The company maintains a market capitalization of merely $5.87 million alongside a GF Score of 55 out of 100, indicating moderate growth prospects but weak performance in profitability (1/10) and financial strength (4/10) categories.
Insider transaction data reveals no buying or selling activity involving CANF shares throughout the preceding 12-month period.
The current P/S ratio registers at 5.32. For a clinical-stage biotechnology company of this scale, market movement is predominantly influenced by trial results rather than underlying financial metrics.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
